Alumis (NASDAQ:ALMS – Get Free Report) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report released on Friday, MarketBeat Ratings reports. They presently have a $25.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 1.50% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus initiated coverage on Alumis in a research report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price objective on the stock. Oppenheimer boosted their target price on shares of Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Monday, March 30th. Raymond James Financial initiated coverage on shares of Alumis in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 price target for the company. Morgan Stanley raised their price target on shares of Alumis from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, March 20th. Finally, Chardan Capital reiterated a “buy” rating and set a $38.00 price objective on shares of Alumis in a research note on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.60.
Read Our Latest Stock Report on ALMS
Alumis Stock Down 0.9%
Alumis (NASDAQ:ALMS – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.05. Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.49 million. On average, sell-side analysts expect that Alumis will post -3.06 EPS for the current year.
Institutional Investors Weigh In On Alumis
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in Alumis in the first quarter worth about $42,000. Strs Ohio raised its position in shares of Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after purchasing an additional 1,500 shares during the last quarter. State of Wyoming acquired a new stake in Alumis in the 1st quarter worth approximately $57,000. Assetmark Inc. acquired a new stake in Alumis in the 1st quarter worth approximately $92,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after purchasing an additional 979 shares during the last quarter.
About Alumis
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
- Five stocks we like better than Alumis
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
